Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release May 28 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

This designation facilitates expedited development and review of the drug, highlighting the urgent need for effective treatments for ALS. The company previously received Orphan Drug Designation for Usnoflast, which provides additional development incentives.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2025, titled "Zydus receives USFDA Fast Track Designation for Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of Amyotrophic Lateral Sclerosis (ALS)".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases